A Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS has dosed the first patients enrolled at Yale MS ...

and the CD3 receptor, which is expressed on the surface of healthy T-cells. The latest pre-clinical R&D update expands the biotech's reach. In July 2015, Immunocore secured $320 million in ...

T cell activation requires a T cell receptor (TCR) to recognize its cognate peptide in the context of an MHC molecule. In addition, the association of CD3 with the TCR–peptide–MHC complex ...

Odronextamab is an investigational bispecific antibody that binds to CD20 expressed on the surface of B cells, and to CD3 receptor expressed on the surface of T cells. This results in local T-cell ...

that consists of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes – as a treatment for unresectable or metastatic uveal melanoma.

Medigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided ... EpimAb's cluster of differentiation 3 (CD3) antibody and TCR-Fab in tandem ...

With a second approach, BCMA-expressing cells can be targeted with ‘bi-specific’ antibodies made up of two parts: one that binds to CD3 receptors on T cells, and another that binds to BCMA.